1. World Health Organization. Improving access to medicines in the South-East Asia region: progress, challenges, priorities. World Health Organization Regional Office for South-East Asia; 2017.
2. Tsoi B, O’Reilly D, Masucci L, Drummond M, Goeree R. Harmonization of HTA-based reimbursement and regulatory approval activities: a qualitative study. J Popul Ther Clin Pharmacol. 2015;22(1):e78–89.
3. Kaplan W, Wirtz V, Mantel-Teeuwisse A, Stolk P, Duthey B, Laing R. Priority medicines for Europe and the world 2013 update. 2013.
http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf
. Accessed 23 Nov 2018.
4. European Commission. Authorisation procedures - The centralised procedure.
https://ec.europa.eu/health/authorisation-procedures-centralised_en
. Accessed 26 Nov 2018.
5. Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Parent F, et al. An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case. Eur J Cancer. 2014;50(18):3089–97.